NTrans Technologies — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

NTrans Technologies is a private, pre-revenue biotech company pioneering a non-viral delivery platform for cell and gene therapies. Its core technology harnesses macropinocytosis, a natural cellular mechanism, to efficiently and safely deliver gene-editing complexes (RNPs) into patient cells ex vivo, with a focus on enhancing CAR-T therapies and other genetic medicines. The company, which is GMP-ready and emphasizes low manufacturing costs and high scalability, is supported by non-dilutive funding and strategic collaborations within the Dutch life sciences ecosystem. NTrans aims to solve key delivery challenges to unlock the full potential of next-generation genetic medicines.

OncologyGenetic DiseasesHematology

Technology Platform

Proprietary non-viral delivery platform that harnesses the natural cellular uptake process of macropinocytosis to deliver gene-editing ribonucleoprotein (RNP) complexes (e.g., CRISPR/Cas9, base editors, prime editors) into cells for ex vivo cell and gene therapies. Described as GMP-ready, modular, and emphasizing high efficiency, cell viability, safety, and scalability.

Opportunities

The massive and growing cell and gene therapy market is constrained by viral vector limitations, creating a high demand for efficient, scalable, and safe non-viral delivery solutions.

NTrans's GMP-ready, modular platform is well-positioned to be licensed by multiple therapeutic developers, enabling revenue through partnerships without the high cost of developing its own drug pipeline.

Recent substantial non-dilutive funding (IPCEI Med4Health) provides a multi-year runway to de-risk the technology and attract strategic partners.

Risk Factors

The non-viral delivery field is intensely competitive, and NTrans must prove its macropinocytosis-based platform is superior to existing and emerging alternatives.

As a pure platform company, its entire business model depends on securing partnerships, making it vulnerable to the priorities and internal capabilities of potential partners.

Despite recent grant funding, the path to sustainable revenue is long and will likely require additional capital infusions.

Competitive Landscape

NTrans competes in the non-viral delivery space for ex vivo cell engineering, facing competition from companies using electroporation (e.g., MaxCyte), lipid nanoparticles, polymer-based systems, and other novel mechanisms. It also competes indirectly with companies developing improved viral vectors. Its differentiation hinges on the specific use of macropinocytosis for RNP delivery, claiming advantages in efficiency, viability, and safety.

More companies in Drug Delivery & Formulation →More companies in Netherlands →